<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444782</url>
  </required_header>
  <id_info>
    <org_study_id>PX115.1.1-201</org_study_id>
    <nct_id>NCT00444782</nct_id>
  </id_info>
  <brief_title>A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.</brief_title>
  <official_title>&quot;Heptovax&quot; - A Phase II, Open-Label Trial Evaluating the Safety and Efficacy of GV1001 in Advanced Hepatocellular Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmexa A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmexa A/S</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of GV1001 in locally advanced or&#xD;
      metastatic HCC. Also the safety of GV1001 and immunogenicity will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (Partial and Complete Response) according to modified RECIST.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Symptomatic Progression (TTSP)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GV1001</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hepatocellular carcinoma diagnosis fulfilling one of the following criteria (as per&#xD;
             the American Association for the Study of Liver Diseases [AASLD] guidelines, see&#xD;
             Appendix 5):&#xD;
&#xD;
               1. Nodule in a cirrhotic or non-cirrhotic liver with a biopsy showing HCC;&#xD;
&#xD;
               2. Nodule in cirrhotic liver where no biopsy is performed:&#xD;
&#xD;
                    -  Nodules between 1-2 cm in a cirrhotic liver with a typical coincidal&#xD;
                       vascular pattern of HCC (i.e. hypervascular with washout in the&#xD;
                       portal/venous phase) in two dynamic studies: either CT scan, contrast&#xD;
                       ultrasound or MRI with contrast.&#xD;
&#xD;
                    -  Nodule larger than 2 cm in a cirrhotic liver with a typical vascular pattern&#xD;
                       of HCC on a dynamic imaging technique.&#xD;
&#xD;
        Please note: HCC in a non-cirrhotic liver can only be diagnosed with a biopsy showing HCC.&#xD;
&#xD;
          -  Measurable disease according to modified RECIST (see Appendix 7).&#xD;
&#xD;
          -  At least one treatment-naïve target lesion (treatment-naïve being defined as not&#xD;
             having been treated with local therapy, such as surgery, radiation therapy, hepatic&#xD;
             arterial embolisation, chemoembolisation, radio-frequency ablation or cryo-ablation).&#xD;
&#xD;
          -  Barcelona Clinic Liver Cancer (BCLC) stage A, B or C (see Appendix 6) (Stage D is&#xD;
             excluded).&#xD;
&#xD;
          -  Child-Pugh stage A (see Appendix 8).&#xD;
&#xD;
          -  Male or female aged 18 years or older.&#xD;
&#xD;
          -  Adequate haematological parameters, as demonstrated by:&#xD;
&#xD;
               -  Haemoglobin greater than or equal to 9.0 g/dL (SI units: 5.6 mmol/L);&#xD;
&#xD;
               -  WBC greater than or equal to 3.0 x 109/L;&#xD;
&#xD;
               -  Platelets greater than or equal to 75 x 109/L.&#xD;
&#xD;
          -  ALT and AST ≤ 5 times the upper limit of normal.&#xD;
&#xD;
          -  Bilirubin &lt; 2 mg/dL.&#xD;
&#xD;
          -  Serum creatinine smaller than or equal to 1.5 mg/dL (SI units: 132 µmol/L).&#xD;
&#xD;
          -  Performance status ECOG 0 or 1.&#xD;
&#xD;
          -  Minimum life expectancy of 3 months at screening.&#xD;
&#xD;
          -  Written informed consent given prior to any study specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HCC amenable to curative treatment or transplantation.&#xD;
&#xD;
          -  History of other malignancies in the last 5 years (10 years in the case of breast&#xD;
             cancer), except for adequately treated non-melanoma skin cancers (Basal Cell&#xD;
             Carcinoma, Squamous Cell Carcinoma) and carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Known history of or co-existing autoimmune disease.&#xD;
&#xD;
          -  Known Central Nervous System (CNS) metastases.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Any medical condition that, in the opinion of the Investigator, may compromise the&#xD;
             compliance of the patient to receive study treatment and follow study procedures.&#xD;
&#xD;
          -  Treatment with any other IMP within 4 weeks prior to cyclophosphamide administration&#xD;
             at Day -3.&#xD;
&#xD;
          -  Known sensitivity to any components of cyclophosphamide, GV1001 or GM-CSF.&#xD;
&#xD;
          -  Concomitant treatment with the following within 4 weeks of pre-treatment with&#xD;
             cyclophosphamide:&#xD;
&#xD;
               -  Anti-tumour treatment (including radiotherapy, chemotherapy, immunotherapy,&#xD;
                  endocrine therapy, cytokines, interferons, protease inhibitors, and gene therapy)&#xD;
                  and vaccines.&#xD;
&#xD;
               -  Chronic corticosteroids (inhaled and topical steroids are permitted including low&#xD;
                  dose steroids at non-immunosuppressive doses e.g. 15 mg prednisolone daily for up&#xD;
                  to 7 days).&#xD;
&#xD;
               -  Herbal medicine either containing hypericum perforacum (e.g., St Johns Wort) or&#xD;
                  claiming to have anti-tumour effects (e.g., Iscador).&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Women of childbearing potential not using reliable and adequate contraceptive methods,&#xD;
             defined as the use of oral, implanted, injectable, mechanical or barrier products for&#xD;
             the prevention of pregnancy; or women who are practising abstinence; or where the&#xD;
             partner is sterile, for example a vasectomy.&#xD;
&#xD;
          -  Unable for any other reason to comply with the protocol (treatment or assessments).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lotte Rosendahl, Pharmacist (CTM)</last_name>
    <role>Study Chair</role>
    <affiliation>Pharmexa A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michel Beaugrand</name>
      <address>
        <city>Bondy</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tim F. Greten</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jordi Bruix</name>
      <address>
        <city>Barcelona</city>
        <zip>E-08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2007</study_first_posted>
  <last_update_submitted>December 17, 2008</last_update_submitted>
  <last_update_submitted_qc>December 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Lotte Rosendahl</name_title>
    <organization>Pharmexa</organization>
  </responsible_party>
  <keyword>Advanced Carcinoma, Hepatocellular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

